A death receptor for TRAIL, TRAIL-R2 (DR5), which had been previously thought to be restricted to tumor tissue, was found to be upregulated on the surface of hepatocytes in liver biopsies from patients with CHB. This evidence concerns the gene TNFSF10 and neoplasm.